New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy | Zendy

Peter F. Hoyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy

Author(s) -

Peter F. Hoyer

Publication year - 2014

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2014.354

Subject(s) - steroid , randomized controlled trial , nephrotic syndrome , medicine , hormone

The best initial therapy for steroid-sensitive nephrotic syndrome (SSNS) in children is subject to ongoing debate. Systematic reviews and meta-analyses have concluded that at least 3 months and up to 7 months of treatment would reduce the number of relapses by 30%. But summarizing small underpowered studies cannot eliminate the basic flaws in design. Two well-powered randomized prospective trials now come to the opposite conclusion, and these results should impact the management of children with SSNS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research